Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-OncologyTM through the development of novel treatments for solid-tumor cancers. IP-001, the first asset from the company’s intellectual property platform, has the potential to transform a routine tumor ablation into a systemically active cancer immunotherapy. Immunophotonics is also exploring the use of its technology platform to help prevent and combat contractions of infectious diseases. Immunophotonics is headquartered in St. Louis, Missouri, with subsidiaries in Bern, Switzerland, and Tianjin, China.
Our issued and pending patents, which are wholly owned by Immunophotonics, support and protect a strong pipeline of convenient, off-the-shelf therapies that are developed to treat patients with cancer. The composition of matter surrounding IP-001 has been patented in over 40 countries representing key markets in oncology across the globe.
Immunophotonics has collaborations with researchers at top universities across the globe. Through these partnerships, many of which are federally funded, Immunophotonics is always making strides toward advancing the science behind the field of Interventional Immuno-Oncology and our understanding of the immune system at large.